Skip to content
Palanor is in early release, with our founding customers.Become a founding customer →
The Real Rate Index45.30.00Palanor: Inflation Pulse50.7+0.09Palanor: Geopolitical Stress60.0-2.16Palanor: Liquidity57.9-0.79Palanor: Capital Tightness47.5+0.91Palanor: Industrial Pulse70.10.00Palanor: AI Margin Compression53.4+0.29Palanor: Consumer Confidence48.6+0.50Palanor: US Dollar Strength46.50.00Palanor: Labor Heat63.2-0.01Palanor: Recession Vocabulary28.1+0.54Palanor: Uncertainty Index53.4+1.24Palanor: US Jobs Health40.30.00Palanor: Energy Transition37.0-0.52Palanor: Reshoring Sentiment22.8+0.54Palanor: AI Substitution28.4-0.24The Social Fabric Index45.70.00Palanor: Geopolitical Anxiety19.4-0.45Palanor: Quit Pressure37.6+0.42The Mania Index88.00.00The Palanor Index57.1-0.51Cost Disease Spread33.20.00Palanor: US vs China49.5-0.17Rise of Socialism Index40.8-0.26The Bubble Memory79.90.00Palanor: Steward Confidence50.8+0.13The Long Watch90.30.00The Reshoring Index55.2+0.00The Capital Return Index81.0-0.75The Discourse Index72.4+1.83The Hesitation Index30.8-6.58Palanor AI Inference Cost Index71.2-0.03The AI Capex Race Index78.4+1.36The Boardroom Index82.5-0.00The Layoff Cycle Index32.8-2.51Capital Deployment Posture Index62.3+1.26The Consumer Health Index41.7-2.96Labor Hours Composite44.40.00The Dollar Erosion Index66.6+0.14Palanor: Risk Appetite36.2+0.83
PalanorPalanor

Company Dossier · Health Care

Gilead Sciences

GILDNasdaqBiotechnologyWILMINGTON, US-DE, USLarge capWebsite ↗
  • S&P 500
  • S&P 100
  • Nasdaq-100
  • Russell 1000

What Gilead Sciences is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.

Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

  • Revenue over the four quarters to June 30, 2026: $30.5 billion, up 5.5% from a year earlier.SEC EDGAR filings (XBRL)
  • Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $12.9 billion, up 38% from a year earlier.SEC EDGAR filings (XBRL)
  • Capital expenditure over the four quarters to June 30, 2026: $0.61 billion, up 22% from a year earlier.SEC EDGAR filings (XBRL)
  • Share buybacks in the fiscal year to December 31, 2025: $1.92 billion.SEC EDGAR filings (10-K)
  • Latest earnings call or results release (August 4, 2026): sentiment 0.70 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.90 of 1.Palanor Discourse
  • Guidance in the last 90 days: 3 outlook figures raised, 2 lowered, 0 held.Guidance Ledger (8-K results releases)
  • Latest annual report (filed February 24, 2026): 1 risk factor added, 1 removed.Risk Factor Changes (10-K Item 1A)
  • Insiders were net sellers in Q3 2026: $15.4 million on the open market.SEC Form 4
  • 2,295 institutional managers reported a position at June 30, 2026 (−36 on the quarter before).SEC Form 13F
  • H-1B filings certified in Q2 2026: 107 (68 a year earlier).U.S. Department of Labor (OFLC)

Company Posture

How Company Posture is measured →

What Gilead Sciences is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.

Steady · Mixed

Expanding ↔ Retrenching

Steady

RetrenchingExpanding

Confident ↔ Hedging

Mixed

HedgingConfident

Pressure

Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).

Credit

How these are built →

Gilead Sciences's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.

Debt on the balance sheet

$26.2B

  • Due within a year $2.4B
  • Longer term $23.8B
  • Default point $14.3B (short + ½ long)

Finance leases included · Jun 30, 2026 filing

Bonds priced, last 12 months

$3.0B

U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.

PricedAmountCouponMaturesSpreadYield
May 14, 2026$500M4.900%2034 (8y)+45bp4.902%
May 14, 2026$1B4.400%2029 (3y)+38bp4.407%
May 14, 2026$500M4.250%2028 (2y)+28bp4.272%
May 14, 2026$1B4.600%2031 (5y)+48bp4.601%
Nov 13, 2024$750M4.800%2029 (5y)+50bp4.803%
Nov 13, 2024$1B5.100%2035 (11y)+70bp5.149%
Nov 13, 2024$1B5.500%2054 (30y)+88bp5.520%
Nov 13, 2024$750M5.600%2064 (40y)+100bp5.649%

From the pricing term sheets Gilead Sciences filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

Cash flow

Business

Gilead Sciences: free cash flow, trailing twelve months

Operating cash flow minus capital expenditure, $ billions, from SEC filings

$12.9BData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Gilead Sciences: operating cash flow and capital expenditure

Trailing twelve months, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Gilead Sciences: revenue, trailing twelve months

$ billions, from SEC filings

$30.5BData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Capital returned and raised

Business

Gilead Sciences: share buybacks by fiscal year

Cash paid to repurchase common stock, $ billions, from the 10-K

$1.9BData to Dec 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Gilead Sciences: debt issued and repaid by fiscal year

Long-term debt, $ billions, from the 10-K

Data to Dec 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Gilead Sciences: debt due within a year and cash

At each balance-sheet date, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Gilead Sciences: interest coverage

Operating income ÷ interest expense, trailing twelve months, from SEC filings

−2.5Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

What the company says

Business

Gilead Sciences: guidance raised minus lowered

Guidance Ledger statements by quarter

1.0Data 22 days ago
ImageDataGuidance Ledger by Palanor · source: SEC EDGAR
Business

Gilead Sciences: earnings call sentiment

Palanor Discourse score per call, −1 to +1

0.70Data to Aug 2026
ImageDataPalanor calculation
Business

Gilead Sciences: earnings call confidence

Palanor Discourse score per call, 0 to 1

0.90Data to Aug 2026
ImageDataPalanor calculation
Business

Gilead Sciences: risk factors added per annual report

New Item 1A risk factors in each 10-K

1.0Data to Feb 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Hiring and ownership

Business

Gilead Sciences: H-1B filings certified

Labor Condition Applications by quarter received

107.0Data to Jun 2026
ImageDataU.S. Department of Labor, Office of Foreign Labor Certification disclosure data, dol.gov
Business

Gilead Sciences: insider net buying

Open-market purchases minus sales by officers and directors, $ millions, by quarter

−$15.4MData 22 days ago
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Gilead Sciences: institutional holders

Managers reporting a position on Form 13F, by quarter

2,295Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

  1. Oct 21, 2026Lobbying
    Lobbying report (GILEAD SCIENCES, INC.)third_quarter 2026 · $2.3 million
  2. Oct 20, 2026Lobbying
    Lobbying report (GILEAD SCIENCES, INC.)third_quarter 2026 · $6.6 million
  3. Oct 20, 2026Lobbying
    Lobbying report (TARPLIN, DOWNS & YOUNG, LLC)third_quarter 2026 · $0.1 million
  4. Oct 20, 2026Lobbying
    Lobbying report (FARRAGUT PARTNERS LLP)third_quarter 2026 · $0.1 million
  5. Oct 20, 2026Lobbying
    Lobbying report (MILLER STRATEGIES, LLC)third_quarter 2026 · $0.1 million
  6. Oct 20, 2026Lobbying
    Lobbying report (THE MCMANUS GROUP)third_quarter 2026 · $0.1 million
  7. Oct 19, 2026Lobbying
    Lobbying report (THE DUBERSTEIN GROUP INC.)third_quarter 2026 · $0.1 million
  8. Oct 19, 2026Lobbying
    Lobbying report (EMPIRE CONSULTING GROUP)third_quarter 2026 · $0.1 million
  9. Sep 15, 2026Patent
    Patent granted: SYSTEMS AND METHODS FOR DETECTING SUSPENDED PARTICLES IN FLUIDSUS 12736455
  10. Sep 8, 2026Patent
    Patent granted: ANTIBODIES THAT BIND TO HUMAN CHEMOKINE (C-C MOTIF) RECEPTOR 8 (CCR8)US 12729241
  11. Sep 1, 2026Patent
    Patent granted: ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAMEUS 12723057
  12. Aug 25, 2026Patent
    Patent granted: METHODS OF ADMINISTERING CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPYUS 12715925
  13. Aug 18, 2026Patent
    Patent granted: METHODS OF ADMINISTERING CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPYUS 12709639
  14. Jun 30, 2026Private credit
    Loans held by business development companies (Gilead Sciences, Inc.)$0.9 million at cost
  15. May 20, 20268-K
    Material agreement signedItem 1.01
  16. May 4, 20268-K
    Shareholder vote resultsItem 5.07
  17. Apr 6, 2026Trademark
    Trademark application: FOCUS
  18. Apr 3, 2026Trademark
    Trademark application: FOCUS
  19. Feb 24, 202610-K
    Annual report (10-K)1 risk factors added, 1 removed
  20. Feb 23, 20268-K
    Material agreement signedItem 1.01
  21. Feb 3, 2026Trademark
    Trademark application: GIGI
  22. Feb 2, 2026Trademark
    Trademark application: GILEAD
  23. Jan 26, 2026Trademark
    Trademark application: GILEAD
  24. Nov 19, 20258-K
    Director or officer changeItem 5.02
  25. Aug 14, 20258-K
    Director or officer changeItem 5.02
  26. May 8, 20258-K
    Shareholder vote resultsItem 5.07
  27. Mar 12, 20258-K
    Director or officer changeItem 5.02
  28. Feb 28, 202510-K
    Annual report (10-K)0 risk factors added, 2 removed
  29. Dec 13, 20248-K
    Director or officer changeItem 5.02
  30. Nov 20, 20248-K
    Material agreement signedItem 1.01
  31. Feb 23, 202410-K
    Annual report (10-K)2 risk factors added, 0 removed

Peers

Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

CompanyRevenueFree cash flowThrough
Amgen AMGN$38.1B$10.2BJun 30, 2026
Regeneron Pharmaceuticals REGN$15.5B$3.8BJun 30, 2026
Vertex Pharmaceuticals VRTX$12.6B$3.8BJun 30, 2026
Biogen BIIB$9.9B$2.4BMar 31, 2026
Incyte INCY$5.4B—Mar 31, 2026
Neurocrine Biosciences NBIX$3.4B$0.6BJun 30, 2026
United Therapeutics UTHR$3.1B$1.1BJun 30, 2026
Exelixis EXEL$2.4B$1.2BJul 3, 2026

Identity

SEC CIK
882095
LEI
549300WTZWR07K8MNV44
Wikidata
Q663596
SAM UEI
FPJMGUK1BYH8

Built from SEC EDGAR filings (public domain), the Guidance and KPI Ledgers, Palanor Discourse, U.S. Department of Labor filings, USPTO, USAspending and Senate lobbying records, and rights-checked news headlines. Updated nightly; this page was built Oct 22, 2026. How the Dossier is built

S&P 500, S&P 100, S&P MidCap 400 and Dow Jones Industrial Average are trademarks of S&P Dow Jones Indices LLC or its affiliates; Nasdaq-100 is a trademark of Nasdaq, Inc.; Russell 1000 is a trademark of FTSE Russell. Membership is shown for identification only. Palanor is not affiliated with or endorsed by the index owners.

Cookies

We only use essential cookies to keep you signed in and remember your theme. No analytics, no tracking, no ads. See the Privacy Policy for the full read.